Findings of two phase III, double-blind, randomised clinical trials comparing omadacycline with standard antibiotics have been published in the New England Journal of Medicine
European regulators have accepted an application from Paratek Pharmaceuticals seeking approval of the broad-spectrum antibiotic omadacycline for two types of infection.